TGTX, 3/1-3/8, -2% loss
On 2/28/2024, TG Therapeutics (TGTX) reported a loss of $0.09 per share on revenue of $43.97 million for the fourth quarter ended December 2023. The consensus estimate was a loss of $0.12 per share on revenue of $40.06 million.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.